|
|
|
|
Vol. 59, Issue 2, 322-330, February 2001
Laboratory of Molecular Medicine, Department of Internal Medicine,
University of Rome-Tor Vergata, Rome-ITALY (M.L.H, R.D., B.G., Y.Y.L.,
P.B., M.F., R.L., G.S.); and Diabetes Branch, National Institute of
Diabetes and Digestive and Kidney Disease, National Institute of
Health, Bethesda, Maryland (D.L.)
Sulfonylureas may stimulate glucose metabolism by protein kinase C
(PKC) activation. Because interaction of insulin receptors with PKC
plays an important role in controlling the intracellular sorting of the
insulin-receptor complex, we investigated the possibility that the
sulfonylurea glimepiride may influence intracellular routing of insulin
and its receptor through a mechanism involving PKC, and that changes in
these processes may be associated with improved insulin action. Using
human hepatoma Hep-G2 cells, we found that glimepiride did not affect
insulin binding, insulin receptor isoform expression, and
insulin-induced receptor internalization. By contrast, glimepiride
significantly increased intracellular dissociation of the
insulin-receptor complex, degradation of insulin, recycling of
internalized insulin receptors, release of internalized radioactivity,
and prevented insulin-induced receptor down-regulation. Association of
PKC-
II and -
with insulin receptors was increased in
glimepiride-treated cells. Selective depletion of cellular PKC-
II
and -
by exposure to
12-O-tetradecanoylphorbol-13-acetate (TPA) or treatment
of cells with PKC-
II inhibitor G06976 reversed the effect of
glimepiride on intracellular insulin-receptor processing. Glimepiride
increased the effects of insulin on glucose incorporation into glycogen
by enhancing both sensitivity and maximal efficacy of insulin. Exposing
cells to TPA or G06976 inhibitor reversed these effects. Results
indicate that glimepiride increases intracellular sorting of the
insulin-receptor complex toward the degradative route, which is
associated with both an increased association of the insulin receptor
with PKCs and improved insulin action. These data suggest a novel
mechanism of action of sulfonylurea, which may have a therapeutic
impact on the treatment of type 2 diabetes.
This article has been cited by other articles:
![]() |
C. Schmitz-Peiffer and T. J. Biden Protein Kinase C Function in Muscle, Liver, and {beta}-Cells and Its Therapeutic Implications for Type 2 Diabetes Diabetes, July 1, 2008; 57(7): 1774 - 1783. [Full Text] [PDF] |
||||
![]() |
A. Melander Kinetics-Effect Relations of Insulin-Releasing Drugs in Patients With Type 2 Diabetes: Brief Overview Diabetes, December 1, 2004; 53(suppl_3): S151 - S155. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Balbis, G. Baquiran, V. Dumas, and B. I. Posner Effect of Inhibiting Vacuolar Acidification on Insulin Signaling in Hepatocytes J. Biol. Chem., March 26, 2004; 279(13): 12777 - 12785. [Abstract] [Full Text] [PDF] |
||||